Remdesivir trial results: NEJM, NIAID and Gilead provide conflicting information

Information shared by the three stakeholders — NEJM, NIAID and Gilead — on critical issues about whether the drug's ability to reduce mortality is statistically significant and which category of patients benefit and who don't stand to gain is both confusing and conflicting. The results of the much awaited randomised double-blind, placebo-controlled trial using remdesivir … Continue reading Remdesivir trial results: NEJM, NIAID and Gilead provide conflicting information

Moderna’s coronavirus vaccine is safe, interim results of phase-1 trial shows

Interim results of Moderna’s phase-1 human clinical trial of novel coronavirus vaccine (mRNA-1273) shows the vaccine is safe. The vaccine was also able to elicit neutralizing antibodies. Interim results of Moderna’s phase-1 human clinical trial of novel coronavirus vaccine (mRNA-1273) that uses messenger RNA (mRNa) shows the vaccine is safe. The vaccine was also able … Continue reading Moderna’s coronavirus vaccine is safe, interim results of phase-1 trial shows

Hydroxychloroquine study: Publisher expresses ‘concerns’ about the paper

The journal that published a paper claiming that hydroxychloroquine had “significant” success in treating COVID-19 patients now has an expression of “concerns” published by its publisher. On March 23, ICMR approved the use of drug as a prophylaxis by healthcare workers and those caring for COVID-19 patients. Aabout 10 days after the Indian Council of … Continue reading Hydroxychloroquine study: Publisher expresses ‘concerns’ about the paper

COVID-19: Doctors cautious over use of malaria drug as prophylaxis

Based on weak evidence, ICMR has recommended hydroxychloroquine as prophylaxis by healthcare workers taking care of COVID-19 cases and asymptomatic household contacts of confirmed cases. No other drug approving agency has green lighted the drug either for prophylaxis or for treatment. Based on the recommendation of the Task Force for coronavirus disease (COVID-19), on March … Continue reading COVID-19: Doctors cautious over use of malaria drug as prophylaxis

A ‘turning point’ in the Zika outbreak

More than 50 years after the infectious pathogen, rubella virus, was identified as the cause of an epidemic of congenital defects, the Centres for Disease Control and Prevention (CDC) in the United States confirmed on April 13 that Zika virus infection during pregnancy causes microcephaly and other severe foetal brain defects. The confirmation of causal … Continue reading A ‘turning point’ in the Zika outbreak

H1N1 vaccine trial in pregnant women set to begin soon in the U.S.

Published in The Hindu on September 10, 2009 The world’s first clinical trial of H1N1 influenza vaccine in pregnant women will be launched this week in the U.S. Pregnant women come under the at-risk category as they are at higher risk of developing severe illness if infected with the influenza virus. Pregnant women will be … Continue reading H1N1 vaccine trial in pregnant women set to begin soon in the U.S.

Single dose of H1N1 vaccine produces robust immune response

Published in The Hindu on September 12, 2009 The safety of 2009 influenza A(H1N1) vaccines that are undergoing clinical trials in different countries has got a shot in the arm. Fear about the safety of the vaccines, which are being tested on a fast-track mode, was expressed by some doctors in a few countries. Much … Continue reading Single dose of H1N1 vaccine produces robust immune response